Ultrapar Participacoes SA
NYSE:UGP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (6.4), the stock would be worth $4.56 (21% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.1 | $5.75 |
0%
|
| 3-Year Average | 6.4 | $4.56 |
-21%
|
| 5-Year Average | 7.8 | $5.53 |
-4%
|
| Industry Average | 4.6 | $3.28 |
-43%
|
| Country Average | 8.3 | $5.88 |
+2%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$38.4B
|
/ |
Jan 2026
R$4.9B
|
= |
|
|
$38.4B
|
/ |
Dec 2026
R$5.2B
|
= |
|
|
$38.4B
|
/ |
Dec 2027
R$5.6B
|
= |
|
|
$38.4B
|
/ |
Dec 2028
R$6.1B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| BR |
|
Ultrapar Participacoes SA
NYSE:UGP
|
30.9B USD | 8.1 | 12.7 | |
| CA |
|
Enbridge Inc
TSX:ENB
|
156.9B CAD | 22.6 | 22.2 | |
| US |
|
Williams Companies Inc
NYSE:WMB
|
88.2B USD | 26.4 | 33.7 | |
| US |
|
Enterprise Products Partners LP
NYSE:EPD
|
82.1B USD | 16.4 | 14.3 | |
| US |
|
Kinder Morgan Inc
NYSE:KMI
|
70.6B USD | 19.5 | 21.4 | |
| US |
|
Energy Transfer LP
NYSE:ET
|
65.6B USD | 14.3 | 15.7 | |
| CA |
|
TC Energy Corp
TSX:TRP
|
86.8B CAD | 21.4 | 25.8 | |
| US |
|
MPLX LP
NYSE:MPLX
|
56.4B USD | 13.2 | 11.5 | |
| US |
|
ONEOK Inc
NYSE:OKE
|
55.1B USD | 14.9 | 16.2 | |
| US |
|
Cheniere Energy Inc
NYSE:LNG
|
54B USD | 8.4 | 10.1 | |
| US |
|
Targa Resources Corp
NYSE:TRGP
|
51.7B USD | 20.5 | 28.1 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 6.8 |
| Median | 8.3 |
| 70th Percentile | 11.3 |
| Max | 288 |
Other Multiples
Ultrapar Participacoes SA
Glance View
Ultrapar Participações S.A. stands as a notable entity in Brazil's diversified industrial landscape, weaving its business intricacies through multiple sectors. Founded in 1937, it has evolved into a conglomerate with operations spanning fuel distribution, chemicals, storage for liquid bulk, and pharmaceuticals. At the heart of its operations is Ipiranga, a leading player in the Brazilian fuel distribution market, which accounts for a substantial portion of its revenue. Through an extensive network of service stations and strategic logistics, Ipiranga supplies not just automotive fuels but also lubricants and vehicular services, tapping into Brazil's continental scale market. Complementing its energy-centric pursuits is Ultracargo, the largest independent bulk liquid storage company in Brazil, focusing on the safe and efficient handling of chemicals, fuels, and liquid bulk. Moreover, Ultrapar strengthens its portfolio with Oxiteno, a key producer of intermediate chemicals and surfactants, which recently joined the Indorama Ventures family, enhancing its reach and specialization in the global market. Additionally, Extrafarma, despite encountering competitive challenges, marks Ultrapar's presence in the pharmaceutical retail sector. Through its varied business arms, Ultrapar orchestrates a diversified revenue model, capitalizing on the synergies among its units to foster growth and stability within Brazil's dynamic economic environment.
